drugset

drugset / Trial / NCT01669226

First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer

NCT01669226 ↗

Phase 2 Completed 215 enrolled Shanghai Gynecologic Oncology Group Fudan University · collab Shanghai Jiao Tong University School of Medicine · collab Shanghai Zhongshan Hospital · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the role of an additional intraperitoneal chemotherapy with cisplatin and etoposide in bulky advanced epithelial ovarian cancer.

Timeline

Start: 2009-04
Primary completion: 2015-09
Completion: 2016-07

Publications

Shi T, Jiang R, Pu H, Yang H, Tu D, Dai Z, Cai Y, Zhang Y, Cheng X, Jia H, Tu R, Wang H, Tang J, Luan Y, Cai S, Zang R; SGOG-OV/AICE Investigators. Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study. Br J Cancer. 2019 Aug;121(5):425-428. doi: 10.1038/s41416-019-0543-1. Epub 2019 Aug 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cisplatin	Other / unclassified	50 mg/m2	Intrathecal
Subject	Etoposide	Small molecule	100 mg/m2	Intrathecal
Background	Carboplatin	Small molecule	—	Intravenous
Background	Docetaxel	Small molecule	60 mg/m2	Intravenous
Background	Docetaxel	Small molecule	75 mg/m2	Intravenous
Background	Paclitaxel	Small molecule	175 mg/m2	Intravenous

Indications